Biodesix, Inc. (BDSX)

Biodesix, Inc.'s stock price has experienced significant fluctuations over the past six months. The stock traded at approximately $6.46 as of early February 2026, with a market capitalization of $51.42 million. Recent financial announcements have been mixed, with preliminary Q4 and full-year 2025 results reporting revenue increases, while Q3 2025 earnings posted a significant miss on EPS. Insider trading activity has also been noted.

Based on the available information, there is no explicit mention of significant demand seasonality for Biodesix, Inc.'s products and services. Consistent revenue growth in its Lung Diagnostics segment across various quarters suggests that demand for Biodesix's diagnostic tests and development services is relatively stable and not heavily impacted by seasonal variations.

Biodesix, Inc. is a diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease, operating within the Health Services sector. The company generates revenue through blood-based diagnostic tests and Development Services, partnering with biopharmaceutical companies to advance new diagnostic assays. Major products include Nodify Lung® Nodule Risk Assessment testing, IQLung® Cancer Treatment Guidance testing, and COVID-19 Tests through a partnership with Bio-Rad Laboratories, Inc.

Biodesix, Inc. is headquartered in Louisville, Colorado, United States, with a key geographic focus on the U.S. The company maintains two accredited laboratories in the U.S., which are New York State CLEP-approved, CAP-accredited, CLIA-certified, and ISO 13485-certified.

Biodesix has established a strong brand reputation, particularly in lung cancer diagnostics, and is expanding its offerings to include other disease states. The company and its leadership have received several recognitions, including rankings in Healthcare Technology Report’s Top 50 Healthcare Technology Companies and recognition as a Top Workplace by The Denver Post. Biodesix was also a finalist for its VeriStrat® and GeneStrat® lung cancer treatment guidance tests and expanded its partnership with Bio-Rad Laboratories.

Biodesix, Inc. has a notable institutional and individual ownership structure. Major institutional owners include Vanguard Total Stock Market Index Fund Investor Shares, Vanguard Extended Market Index Fund Investor Shares, and Telemark Asset Management, LLC. Key individual insiders with significant holdings include Lawrence T. Kennedy Jr., Matthew Strobeck, and Jack W. Schuler.